Helix BioPharma Corp. (HBP.TO) Research

Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.

Market snapshot

Symbol
HBP.TO
Price
$1.42
Day change
0.00%
Market cap
$108.5M
P/E ratio
-32.27x
52-week range
0.84-5.4
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 5 months

Peer companies

  • Cardiol Therapeutics Inc. (CRDL.TO)
  • Cybin Inc. (CYBN.NE)
  • HLS Therapeutics Inc. (HLS.TO)
  • Jushi Holdings Inc. (JUSH.CN)
  • Cannara Biotech Inc. (LOVE.V)
  • Medicenna Therapeutics Corp. (MDNA.TO)
  • Satellos Bioscience Inc. (MSCL.TO)
  • Quipt Home Medical Corp. (QIPT.TO)

Open Helix BioPharma Corp. (HBP.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.